As per MRFR analysis, the South Korea CAR T Cell Therapy Market Size was estimated at 200 (USD Million) in 2023.The South Korea CAR T Cell Therapy Market Industry is expected to grow from 231(USD Million) in 2024 to 1,375 (USD Million) by 2035. The South Korea CAR T Cell Therapy Market CAGR (growth rate) is expected to be around 17.605% during the forecast period (2025 - 2035).
The market for CAR T cell therapy is expanding significantly in South Korea thanks to higher investments in biotechnology-related research and development. To improve its healthcare system, the South Korean government has aggressively encouraged the development of cellular therapies, especially in oncology.
Initiatives to expedite regulatory procedures for novel therapies demonstrate this support, which makes it simpler for businesses to launch their goods.
Funding for education and training in this specialist field as well as the dedication to growing healthcare infrastructure are important market factors that help local businesses stay up to date with developments throughout the world.
Personalized medicine, which focuses on adjusting treatments to each patient's unique genetic profile, has been increasingly popular in recent years. This tendency has promoted innovation in CAR T cell products by creating new opportunities for collaboration between industry and academia.
The region's growing prevalence of chronic illnesses like cancer has also raised the demand for efficient therapies, which is driving further research. Furthermore, South Korea's distinct position as a pioneer in technology and digital health integration makes it easier to produce cutting-edge solutions, which presents a chance to investigate for bettering treatment results.
Given the intricate production procedures required, emphasis is being placed on investments in manufacturing capabilities for CAR T cell therapy. In order to improve accessibility, businesses are seeking to implement scalable and effective production procedures.
A paradigm shift in healthcare practices is evident in South Korea's increasing knowledge and acceptance of immunotherapy as a mainstream cancer treatment, which is conducive to the expansion of CAR T Cell treatments. All things considered, these patterns highlight South Korea's aggressive strategy to establish itself as a major force in the worldwide CAR T cell therapy market.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Increasing Incidence of Cancer
The South Korea CAR T Cell Therapy Market Industry is being significantly driven by the rising incidence of cancer among the population. According to the Korean Central Cancer Registry, there were approximately 234,000 new cancer cases reported in 2020 alone.
This alarming figure indicates a growing need for advanced therapeutic solutions, particularly CAR T cell therapy, which has shown promising results in treating hematological malignancies. Entities such as the Korean Cancer Association are actively involved in raising awareness and supporting research, which aligns with the heightened focus on innovative treatments.
The government's initiatives to enhance cancer care and investments in Research and Development for targeted therapies are further aiding this market's expansion. Given the increasing cancer prevalence, forecasts suggest that the demand for CAR T cell therapies will escalate, contributing to substantial market growth in South Korea.
Advancements in Genomic Research
Technological advancements in genomic research are another critical driver fueling the South Korea CAR T Cell Therapy Market Industry. With significant investments into biotechnology and genotyping technologies by major institutions such as the Korea Institute of Science and Technology, improvements in personalized medicine are on the rise.
Notably, there has been a rapid increase in the number of patents filed related to CAR T cell therapies, indicating a flourishing innovation landscape.
This environment fosters R&D that not only enhances the efficacy of these therapies but also expands their application in various types of cancers. As the scientific community emphasizes the importance of tailormade cancer therapies, the resulting breakthroughs in this domain are likely to boost market dynamics.
Government Support for Cancer Research
The South Korean government continues to play a pivotal role in shaping the future of the CAR T Cell Therapy Landscape. Through supportive regulations and funding for innovative cancer treatments, policies have been established to reinforce the infrastructure required for Research and Development.
For instance, the Biohealth Industry Promotion Act, which was enacted in 2020, aims to foster an ecosystem for biotechnology development.
As of 2022, over USD 400 million was allocated to support research initiatives focusing on advanced therapies, including CAR T cell advancements. This governmental backing not only accelerates development cycles but also ensures that South Korea remains competitive in the global CAR T cell landscape, appealing to both researchers and investors alike.
Rise of Biotech Startups
The rise of biotechnology startups specializing in CAR T cell therapies is significantly impacting the South Korea CAR T Cell Therapy Market Industry. Data from the Ministry of Health and Welfare shows that there has been a 25% increase in the number of biotech startups focusing on cancer treatment technologies over the past three years.
Startups like Y-Biologics and GC Cell are gaining traction, actively bringing innovative CAR T products to market. These startups often collaborate with established pharmaceutical companies as well as research institutions to optimize their research outcomes.
This influx of fresh ideas and approaches is vital for expanding the range of treatment options available in South Korea, accommodating the rising demand for state-of-the-art oncology solutions.
The South Korea CAR T Cell Therapy Market within the Therapeutic Area segment is experiencing significant growth and transformation, driven primarily by advancements in technology and increasing clinical applications.
Oncology remains at the forefront of this market, with CAR T cell therapies demonstrating notable efficacy in treating various hematologic malignancies such as leukemia and lymphoma.
The success of these therapies in oncology is largely attributed to rigorous clinical trials and the establishment of specialized treatment centers across South Korea, which enhance patient access and facilitate innovative treatment protocols.
In addition, Autoimmune Diseases represent an emerging area of interest within the South Korea CAR T Cell Therapy Market as researchers explore the potential for CAR T cell therapies to modify immune responses and alleviate symptoms of conditions like rheumatoid arthritis and lupus.
This evolving interest reflects a broader trend within the pharmaceutical industry, emphasizing personalized medicine approaches that leverage genetic and cellular modalities for targeted interventions.
Furthermore, the segment addressing Infectious Diseases is gaining traction as researchers investigate CAR T cell applications in combating viral infections and enhancing immune responses against pathogens.
This area presents substantial opportunities for development, especially in the context of South Korea’s robust healthcare infrastructure and supportive government policies promoting innovative therapeutic research.
Overall, the dynamic therapeutic landscape for CAR T cell therapy in South Korea demonstrates a well-rounded potential to address diverse medical needs while capitalizing on the continuous technological evolution and heightened research efforts in the region.
The confluence of these factors contributes to a strong foundation for the South Korea CAR T Cell Therapy Market, positioning it well for future expansion across these therapeutic applications.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The South Korea CAR T Cell Therapy Market is witnessing significant developments in the Cell Source segment, reflecting various innovative strategies in healthcare. Autologous therapies, which involve using a patient's own cells, hold a promising position due to their personalized nature, thereby reducing the risk of rejection.
Allogeneic sources derived from healthy donors are gaining traction as they have the potential for scalability and reduced treatment timelines, positioning them favorably in clinical settings. Gene-edited approaches are highlighting advancements in technology, focusing on improving the safety and efficacy of therapies, thus catering to a critical demand in the market.
South Korea's robust Research and Development initiatives, supported by government investments in biotechnology, are paving the way for rapid advancements in these cell-sourcing methods. These evolving dynamics within the Cell Source segment underline its importance in enhancing patient outcomes and driving the overall growth of the South Korea CAR T Cell Therapy Market.
The market trends reflect a strong inclination towards personalized medicine and genetically tailored therapies, which are becoming vital components in the approach to treating various cancers and autoimmune diseases.
The South Korea CAR T Cell Therapy Market is witnessing a notable evolution in its Indication segment, which encompasses various diseases such as Acute Lymphoblastic Leukemia, non-Hodgkin lymphoma, and Multiple Myeloma.
Acute Lymphoblastic Leukemia holds significant importance due to its prevalence in pediatric cases, driving a considerable demand for advanced therapeutic options. Non-Hodgkin Lymphoma, with various subtypes, is another area where CAR T Cell therapies are making remarkable advancements, providing hope for patients who have limited treatment options available.
Meanwhile, Multiple Myeloma represents a critical focus area for ongoing Research and Development initiatives as the need for effective and targeted therapies continues to rise. The growth trends indicate that these therapies not only improve survival rates but also enhance the quality of life for patients.
With government support and innovation from local biotechnology firms, the South Korea CAR T Cell Therapy Market is positioned to capitalize on these key indications, driven by continuous research efforts and increasing approval of therapeutic options.
The South Korea CAR T Cell Therapy Market showcases a diverse landscape with significant engagement from various End-users such as Hospitals, Research Institutes, and Cancer Treatment Centers. Hospitals are crucial in providing immediate patient care and administering therapies, often serving as the front line for CAR T cell treatments due to their patient volume and advanced facilities.
Research Institutes play an important role in advancing the scientific understanding of CAR T cell therapies, focusing on clinical trials and innovative research that aids in refining treatment protocols and improving outcomes.
Cancer Treatment Centers are dedicated facilities that specialize in comprehensive cancer care, including CAR T cell therapies and are instrumental in focusing on patient-specific treatment plans, thus driving improved patient experiences and outcomes.
Moreover, the continuous investment in healthcare infrastructure in South Korea, along with strong government support for medical innovation, is likely to foster growth in these areas, aiding in the effective treatment of various cancers and enhancing the overall South Korea CAR T Cell Therapy Market industry.
Each segment serves a pivotal function that not only contributes to revenue generation but also addresses the diverse needs of patients requiring advanced cancer therapies, ensuring tailored approaches for treatment and care.
The South Korea CAR T Cell Therapy Market is experiencing significant growth due to increasing investments in advanced cancer treatment methodologies and the rising prevalence of hematological malignancies.
This market showcases a competitive landscape characterized by a blend of local and international players striving to leverage innovations in cellular therapies, which have shown transformative potential in treating various forms of cancer.
Companies involved in this market are focusing on research and development to enhance therapeutic efficacy while also addressing regulatory and manufacturing challenges unique to the region. The evolving landscape is propelled by collaborations, partnerships, and advancements in biomanufacturing technologies, which bolster the market's resilience against both domestic and global challenges.
Allogene Therapeutics has established a notable presence in the South Korea CAR T Cell Therapy Market by leveraging its innovative allogeneic CAR T cell platform technology. The company emphasizes the development of off-the-shelf CAR T cell therapies that promise to improve accessibility for patients in need.
This model not only allows for quicker treatment response but also enhances scalability and production efficiency. Allogene Therapeutics benefits from robust research capabilities and strategic partnerships within South Korea, which enhance its operational strength in a competitive market.
The firm's ability to bring advanced therapeutic solutions to patients facing various malignancies showcases its commitment to improving cancer care within this growing market. Sorrento Therapeutics has made impactful strides in the South Korea CAR T Cell Therapy Market through a robust portfolio of innovative therapeutic solutions focused on cancer treatment.
The company develops multiple CAR T cell therapies that prioritize both efficacy and safety, targeting various hematologic cancers while also exploring options for solid tumors. In the South Korean context, Sorrento Therapeutics is recognized for its agile approach to research and its ability to quickly adapt to market demands, along with its strategic mergers and acquisitions that bolster its presence in the region.
The company’s investments in local partnerships for clinical trials and product development further solidify its foothold in the Korean market. Their emphasis on innovation, alongside a solid market presence, positions Sorrento Therapeutics as a pivotal player in advancing CAR T cell therapy options in South Korea.
Key Companies in the South Korea CAR T Cell Therapy Market Include
The South Korea CAR T Cell Therapy Market has seen significant developments recently, with major companies like Bristol-Myers Squibb, Novartis, and Gilead Sciences expanding their presence. In March 2023, Allogene Therapeutics announced a collaboration with Samsung Biologics to enhance its cell therapy manufacturing capabilities in South Korea.
Additionally, in April 2023, Sorrento Therapeutics initiated its CAR T Cell development program, focusing on innovative therapies in the region. Mergers and acquisitions have also been noteworthy, with KITE Pharma being acquired by Gilead Sciences in a deal that continues to influence competitive dynamics in the market.
Over recent years, specifically in 2021, LG Chem strengthened its Research and Development capabilities by teaming up with local universities to foster innovation in cell therapy technologies. The South Korean government is actively supporting this sector through its Healthcare Innovation Strategy, aimed at boosting biopharmaceutical technologies and expanding access to advanced cancer treatments.
The growth in this sector is also reflected in increasing investments aimed at enhancing the local manufacturing landscape for CAR T Cell therapies, thereby improving patient access and treatment options.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 200.0(USD Million) |
| MARKET SIZE 2024 | 231.0(USD Million) |
| MARKET SIZE 2035 | 1375.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 17.605% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | Allogene Therapeutics, Sorrento Therapeutics, Bristol Myers Squibb, Novartis, Samsung Biologics, KITE Pharma, Gilead Sciences, Adaptimmune, Bluebird Bio, OncoOne, AbbVie, Roche, LG Chem, Celltrion, Celyad Oncology |
| SEGMENTS COVERED | Therapeutic Area, Cell Source, Indication, End User |
| KEY MARKET OPPORTUNITIES | Growing investment in biotech, Rising prevalence of cancer, Favorable government policies, Collaborations with research institutions, Advancements in personalized medicine |
| KEY MARKET DYNAMICS | increasing cancer prevalence, advanced research initiatives, favorable regulatory environment, rising healthcare expenditure, growing patient awareness |
| COUNTRIES COVERED | South Korea |
Frequently Asked Questions (FAQ) :
The expected market size of the South Korea Car T Cell Therapy Market in 2024 is 231.0 million USD.
By 2035, the market value of the South Korea Car T Cell Therapy Market is expected to reach 1375.0 million USD.
The anticipated CAGR for the South Korea Car T Cell Therapy Market from 2025 to 2035 is 17.605%.
By 2035, the oncology therapeutic area is expected to dominate with a market value of 850.0 million USD.
In 2024, the market size for Autoimmune Diseases in the South Korea Car T Cell Therapy Market is valued at 40.0 million USD.
The Infectious Diseases segment is projected to grow to 225.0 million USD by 2035.
Major players in the market include Allogene Therapeutics, Sorrento Therapeutics, Bristol Myers Squibb, and Novartis among others.
Key growth drivers include advancements in cancer treatments and the increasing prevalence of autoimmune diseases.
Challenges may include regulatory hurdles and high costs associated with Car T Cell therapies.
The competition landscape is intensifying as more companies, such as Gilead Sciences and Roche, are entering the market with innovative therapies.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
